-
Applying an ensemble classification tree approach to the prediction of completion of a 12-step facilitation intervention with stimulant abusers.
Doyle SR, Donovan DM. Applying an ensemble classification tree approach to the prediction of completion of a 12-step facilitation intervention with stimulant abusers. Psychology of Addictive Behaviors 2014;28(4):1127-1143.
-
Improving treatment for opioid dependence: A perspective from the Ohio Valley Node of the NIDA Clinical Trials Network.
Winstanley EL, Brigham GS, Babcock D, Winhusen TJ. Improving treatment for opioid dependence: A perspective from the Ohio Valley Node of the NIDA Clinical Trials Network. Progress in Community Health Partnerships: Research, Education, and Action 2014;8(1):99-107.
-
Is level of exposure to a 12-step facilitation therapy associated with treatment outcome?
Wells EA, Donovan DM, Daley DC, Doyle SR, Brigham GS, Garrett SB, Ingalsbe MH, Hatch-Maillette MA, Perl HI, Walker NR. Is level of exposure to a 12-step facilitation therapy associated with treatment outcome? Journal of Substance Abuse Treatment 2014;47(4):265-274.
-
Treatment adherence and competency ratings among therapists, supervisors, study-related raters and external raters in a clinical trial of 12-step facilitation for stimulant users.
Peavy KM, Guydish JR, Manuel JK, Campbell BK, Lisha N, Le T, Delucchi KL, Garrett SB. Treatment adherence and competency ratings among therapists, supervisors, study-related raters and external raters in a clinical trial of 12-step facilitation for stimulant users. Journal of Substance Abuse Treatment 2014;47(3):222-228.
-
Who benefits from additional drug counseling among prescription opioid dependent patients receiving buprenorphine-naloxone and standard medical management?
Weiss RD, Griffin ML, Potter JS, Dodd DR, Dreifuss JA, Connery HS, Carroll KM. Who benefits from additional drug counseling among prescription opioid dependent patients receiving buprenorphine-naloxone and standard medical management? Drug and Alcohol Dependence 2014;104(1):118-122.
-
Racial/ethnic match and treatment outcomes for women with PTSD and substance use disorders receiving community-based treatment.
Ruglass LM, Hien DA, Hu M, Campbell ANC, Caldeira NA, Miele GM, Chang DF. Racial/Ethnic Match and Treatment Outcomes for Women with PTSD and Substance Use Disorders Receiving Community-Based Treatment. Community Mental Health Journal 2014;50(7):811-822.
-
Preliminary findings on the association between clients’ perceived helpfulness of substance abuse treatment and outcomes: Does race matter?
Montgomery L, Sanning B, Litvak N, Peters EN. Preliminary findings on the association between clients' perceived helpfulness of substance abuse treatment and outcomes: Does race matter? Drug and Alcohol Dependence 2014;139(1):152-158.
-
Dissemination activities: A critical new role for substance abuse treatment organizations.
Fields D, Blum TC, Roman PM. Dissemination activities: A critical new role for substance abuse treatment organizations. Journal of Behavioral Health Services & Research 2014;41(4):473-487.
-
HIV risk reduction with buprenorphine-naloxone or methadone: Findings from a randomized trial.
Woody GE, Bruce RD, Korthuis PT, Chhatre S, Hillhouse MP, Jacobs P, Sorensen JL, Saxon AJ, Metzger D, Ling W. HIV risk reduction with buprenorphine-naloxone or methadone: Findings from a randomized trial. Journal of Acquired Immune Deficiency Syndromes 2014;66(3):288-293.
-
Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence.
Winhusen TJ, Kropp FB, Lindblad R, Douaihy AB, Haynes LF, Hodgkins C, Chartier K, Kampman KM, Sharma G, Lewis DF, VanVeldhuisen PC, Theobald J, May J, Brigham GS. Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence. Journal of Clinical Psychiatry 2014;75(7):757-764.